Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Rating of “Hold” by Brokerages

Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) have been given a consensus recommendation of “Hold” by the seven brokerages that are presently covering the company, Marketbeat reports. Six investment analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $22.25.

Separately, StockNews.com lowered Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, April 2nd.

Aclaris Therapeutics Stock Performance

Shares of Aclaris Therapeutics stock opened at $1.15 on Friday. Aclaris Therapeutics has a one year low of $0.59 and a one year high of $11.12. The stock has a market cap of $81.95 million, a P/E ratio of -1.06 and a beta of 0.06. The stock’s fifty day moving average is $1.16 and its 200 day moving average is $1.16.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.04. Aclaris Therapeutics had a negative return on equity of 61.03% and a negative net margin of 248.28%. The business had revenue of $2.40 million during the quarter, compared to analyst estimates of $1.99 million. Analysts predict that Aclaris Therapeutics will post -0.78 EPS for the current year.

Insider Activity

In other news, major shareholder Braden Michael Leonard acquired 528,621 shares of the business’s stock in a transaction dated Thursday, June 13th. The stock was purchased at an average price of $1.15 per share, for a total transaction of $607,914.15. Following the completion of the transaction, the insider now directly owns 11,007,134 shares in the company, valued at approximately $12,658,204.10. The acquisition was disclosed in a filing with the SEC, which is available through this link. Insiders bought a total of 1,678,621 shares of company stock worth $1,857,414 over the last 90 days. Corporate insiders own 6.40% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in ACRS. Corton Capital Inc. purchased a new position in Aclaris Therapeutics in the third quarter worth about $102,000. Vontobel Holding Ltd. grew its position in Aclaris Therapeutics by 128.8% in the fourth quarter. Vontobel Holding Ltd. now owns 30,268 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 17,040 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new position in Aclaris Therapeutics in the first quarter worth about $39,000. SG Americas Securities LLC grew its position in Aclaris Therapeutics by 69.5% in the first quarter. SG Americas Securities LLC now owns 32,843 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 13,461 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in Aclaris Therapeutics by 115.5% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 43,784 shares of the biotechnology company’s stock worth $46,000 after acquiring an additional 23,467 shares in the last quarter. Hedge funds and other institutional investors own 98.34% of the company’s stock.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.